Risk factor assessments can rule out the need for CT angiography for pulmonary embolism, according to a new study published in Radiology.
Risk factor assessments can rule out the need for CT angiography for pulmonary embolism, according to a new study published in Radiology.
CT angiograms were negative for pulmonary embolism (PE) in 90.2% of 2003 patients, according to researchers at the University of California, Irvine. Among the 197 patients positive for PE, 97.5% had one or more risk factors. The risk factors were age, gender, cancer, history of immbolization, excess estrogen rate, a history of venous thromboembolism, and disorders that cause blood to clot easily.
All risk factors except gender were considered statistically significant. Age of 65 years or older and immobilization were the most common risk factors in positive PE patients. Risk factor assessment had a sensitivity of 97.5% and a negative predictive value of 99% in all patients.
Of the patients negative for PE, 28.8% had no risk factors. Excluding age and gender brought that figure to 62%.
Results were published online June 15 (Epub ahead of print).
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.